Results 151 to 160 of about 1,341 (168)
Some of the next articles are maybe not open access.

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Ophthalmology, 2022
Mario Salvi   +2 more
exaly  

Ototoxicity and Teprotumumab

Annals of Otology, Rhinology and Laryngology, 2022
Julie Highland   +2 more
exaly  

Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy

Expert Opinion on Investigational Drugs, 2020
Terry J Smith, Christine C Nelson
exaly  

Methylprednisolone/teprotumumab

Reactions Weekly, 2022
openaire   +1 more source

Prednisone/teprotumumab

Reactions Weekly, 2021
openaire   +1 more source

Sertraline/teprotumumab

Reactions Weekly, 2022
openaire   +1 more source

Methylprednisolone/Teprotumumab

Reactions Weekly, 2023
openaire   +1 more source

Corticosteroids/teprotumumab

Reactions Weekly, 2022
openaire   +1 more source

Prednisone/teprotumumab

Reactions Weekly, 2022
openaire   +1 more source

Teprotumumab/thiamazole

Reactions Weekly, 2022
openaire   +1 more source
thyroid eye disease
thyroid eye disease ted
proptosis
graves’ orbitopathy
hyperglycemia
graves ophthalmopathy
antibodies, monoclonal, humanized
humans
3. good health
previous   14  15  16  17  

Home - About - Disclaimer - Privacy